secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2026-09-10T20:16:12+00:00
Accession:  0001093557-26-000167
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom appoints Glenn Boehnlein, former Stryker CFO, to board
-------------------------------------------------------------

- Board expanded to 13 directors; Boehnlein appointed effective Sept 10, 2026.
- Boehnlein is former VP & CFO of Stryker; brings MedTech financial leadership.
- Appointed to Operations & Innovation and Audit Committees.
- Received initial RSU grant worth $500,000 vesting over 3 years; annual grant $347,500.
- CEO Jake Leach cites Boehnlein's track record in growth and capital allocation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000167/0001093557-26-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355726000167/dxcm-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001093557-26-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer